Background
In today’s clinical infectious disease arena, bacterial infectious diseases are becoming extremely worrisome for two main reasons:
-
Bacteria are highly capable of generating a plethora of resistance mechanisms that quickly render antibiotic drugs inactive.
-
There is a severe dearth in novel anti-bacterial drugs to combat lethal and multi-drug resistant bacteria.
This situation of “Bad Bugs, No Drugs”, as described by the Infectious Diseases Society of America (IDSA), is likely to worsen over the next two decades due to an aging population, more immune-suppressed patients, increased use of invasive devices and drug resistant bacteria.